Nutritional and metabolic correlates of cardiovascular and bone disease in HIV-infected patients

American Journal of Clinical Nutrition

Volumn 94, Issue 6, 2011, Pages

  Fitch, Kathleen ^a   Grinspoon, Steven ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; ABACAVIR; ANTIVIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; VITAMIN D;

AGE; BODY MASS; BONE DENSITY; BONE DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONFERENCE PAPER; CONGESTIVE CARDIOMYOPATHY; DIABETES MELLITUS; DYSLIPIDEMIA; FRACTURE; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; LIFESTYLE; METABOLIC DISORDER; NUTRITION; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; VITAMIN SUPPLEMENTATION;

ANTI-HIV AGENTS; BONE DISEASES; CARDIOVASCULAR DISEASES; HIV; HIV INFECTIONS; HUMANS; IMMUNITY; LIFE STYLE; NUTRITION DISORDERS; NUTRITIONAL STATUS; VIRAL LOAD;

EID: 82355165144     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.3945/ajcn.111.012120     Document Type: Conference Paper

References (63)

1. Grinspoon S. Nutritional correlates of metabolic complications, CVD, bone, insulin sensitivity: what do we do? Nutrition in clinical management of HIV infected adolescents and adults including pregnant and lactating women: what do we know, and what can we do, and where do we go from here? Washington, DC: 2010.
2. Data Collection on Adverse Events of Anti-HIV drugs (D: A:D) Study Group, Smith C, Sabin CA, Lundgren JD, Thiebaut R, Weber R, Law M, D'Arminio Monforte A, Kirk O, Friis-Moller N, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D: A:D Study. AIDS 2010;24:1537-48. (Published erratum appears in AIDS 2011:25:883.)
3. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006;20:2165-74. (Pubitemid 44684707)
4. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007;92:2506-12. (Pubitemid 47037350)
5. Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002;30:471-7.
6. Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, Visscher BR, Margolick JB, Dobs AS. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005;165:1179-84. (Pubitemid 40720744)
7. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, Monforte A, Pradier C, Morfeldt L, Mateu S, Law M, et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS 2003;17:1179-93. (Pubitemid 36667761)
8. Vittecoq D, Escaut L, Chironi G, Teicher E, Monsuez JJ, Andrejak M, Simon A. Coronary heart disease in HIV-infected patients in the highly active antiretroviral treatment era. AIDS 2003;17(suppl 1):S70-6. (Pubitemid 36667783)
9. Lifson AR, Neuhaus J, Arribas JR, van den Berg-Wolf M, Labriola AM, Read TR. Smoking-related health risks among persons with HIV in the Strategies for Management of Antiretroviral Therapy clinical trial. Am J Public Health 2010;100:1896-903.
10. Joy T, Keough HM, Hadigan C, Lee H, Dolan SE, Fitch KV, Liebau J, Lo J, Johnsen S, Hubbard JL, et al. Dietary fat intake and relationship to serum lipid levels among HIV-infected subjects with metabolic abnormalities in the era of HAART. AIDS 2007;21:1591-600. (Pubitemid 47075480)
11. Friis-Miller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, Thiebaut R, De Wit S, Kirk O, Fontas E, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723-35. (Pubitemid 46658704)
12. Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, D'Arminio Monforte A, Friis-Moller N, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008;371:1417-26.
13. Satchell C, O'Connor E, Peace A, Cotter A, Sheehan G, Tedesco T, Doran P, Powderly W, Kenny D, Mallon P, eds. Platelet hyper-reactivity in HIV-1-infected patients on abacavir-containing ART. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada, 2009.
14. Hsue PY, Hunt PW, Schnell A, Kalapus SC, Hoh R, Ganz P, Martin JN, Deeks SG. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 2009;23: 1059-67.
15. Stategies for Management of Anti-Retroviral Therapy/INSIGHT: DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008;22:F17-24.
16. Kuller L, SMART Study Group. Elevated levels of interleukin-6 and D-dimer are associated with an increased risk of death in patients with HIV. 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, 2008.
17. Shlay JC, Bartsch G, Peng G, Wang J, Grunfeld C, Gilbert CL, Visnegarwala F, Raghavan SS, Xiang Y, Farrough M, et al. Long-term body composition and metabolic changes in antiretroviral naive persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy. J Acquir Immune Defic Syndr 2007;44:506-17. (Pubitemid 46594893)
18. Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N, Davis B, Sax P, Stanley T, Wilson PW, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001;32:130-9. (Pubitemid 32150958)
19. Wohl D, Scherzer R, Heymsfield S, Simberkoff M, Sidney S, Bacchetti P, Grunfeld C. The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men. J Acquir Immune Defic Syndr 2008;48:44-52. (Pubitemid 351600858)
20. Hadigan C, Kamin D, Liebau J, Mazza S, Barrow S, Torriani M, Rubin R, Weise S, Fischman A, Grinspoon S. Depot-specific regulation of glucose uptake and insulin sensitivity in HIV-lipodystrophy. Am J Physiol Endocrinol Metab 2006;290:E289-98.
21. Hadigan C, Meigs JB, Wilson PW, D'Agostino RB, Davis B, Basgoz N, Sax PE, Grinspoon S. Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution. Clin Infect Dis 2003;36:909-16. (Pubitemid 36403525)
22. Guaraldi G, Stentarelli C, Zona S, Orlando G, Carli F, Ligabue G, Lattanzi A, Xaccherini G, Rossi R, Modena MG, et al. Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjects. Atherosclerosis 2010;208:222-7.
23. Lo J, Abbara S, Shturman L, Soni A, Wei J, Rocha-Filho JA, Nasir K, Grinspoon SK. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS 2010;24:243-53.
24. Fitch K, Lo J, Abbara S, Ghoshhajra B, Shturman L, Soni A, Sacks R, Wei J, Grinspoon S. Increased coronary artery calcium score and noncalcified plaque among HIV-infected men: relationship to metabolic syndrome and cardiac risk parameters. J Acquir Immune Defic Syndr 2010;55:495-9.
25. Lichtenstein KA, Armon C, Buchacz K, Chmiel JS, Buckner K, Tedaldi EM, Wood K, Holmberg SK, Brooks JT. Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis 2010;51:435-47.
26. Triant VA, Regan S, Lee H, Sax PE, Meigs JB, Grinspoon SK. Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system. J Acquir Immune Defic Syndr 2010;55:615-19.
27. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-96. (Pubitemid 44837777)
28. Tien PC, Choi AI, Zolopa AR, Benson C, Tracy R, Scherzer R, Bacchetti P, Shlipak M, Grunfeld C. Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr 2010;55:316-22.
29. Law MG, Friis-Moller N, El-Sadr WM, Weber R, Reiss P, D'Arminio Monforte A, Thiebaut R, Morfeldt L, De Wit S, et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med 2006;7:218-30.
30. Silverberg MJ, Leyden W, Hurley L, Go AS, Quesenberry CP Jr, Klein D, Horberg MA. Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection. Ann Intern Med 2009;150:301-13.
31. Miller J, Brown D, Amin J, Kent-Hughes J, Law M, Kaldor J, Cooper DA, Carr A. A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia. AIDS 2002;16:2195-200. (Pubitemid 35387274)
32. Dube MP, Wu JW, Aberg JA, Deeg MA, Alston-Smith BL, McGovern ME, Lee D, Shriver SL, Martinez AI, Greenwald M, et al. Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148. Antivir Ther 2006;11:1081-9. (Pubitemid 44955184)
33. Gerber MT, Mondy KE, Yarasheski KE, Drechsler H, Claxton S, Stoneman J, DeMarco D, Powderly WG, Tebas P. Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy. Clin Infect Dis 2004;39:419-25. (Pubitemid 39050492)
34. Wohl DA, Tien HC, Busby M, Cunningham C, MacIntosh B, Napravnik S, Danan E, Donovan K, Hossenipour M, Simpson J. Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise for counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia. Clin Infect Dis 2005;41:1498-504. (Pubitemid 41579995)
35. Hadigan C, Liebau J, Torriani M, Andersen R, Grinspoon S. Improved triglycerides and insulin sensitivity with 3 months of acipimox in human immunodeficiency virus-infected patients with hypertriglyceridemia. J Clin Endocrinol Metab 2006;91:4438-44. (Pubitemid 44833420)
36. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, Segal Y, Aberg JA, Blaschke T, Alston B, Fang F, Kosel B, Aweeka F. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 2002;16:569-77. (Pubitemid 34218852)
37. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA 2000;284:472-7. (Pubitemid 30484481)
38. Hadigan C, Meigs JB, Rabe J, D'Agostino RB, Wilson PW, Lipinska I, Tofler GH, Grinspoon S. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 2001;86:939-43. (Pubitemid 32207521)
39. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. [see comment] N Engl J Med 2007;356:2457-71. (Pubitemid 46919772)
40. Fitch KV, Anderson EJ, Hubbard JL, Carpenter SJ, Waddell WR, Caliendo AM, Grinspoon SK. Effects of a lifestyle modification program in HIV-infected patients with the metabolic syndrome. AIDS 2006;20:1843-50. (Pubitemid 44358902)
41. Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007;357:2359-70. (Pubitemid 350223390)
42. Stanley TL, Falutz J, Mamputu JC, Soulban G, Potvin D, Grinspoon SK. Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction. AIDS 201125:1281-8.
43. Falutz J, Mamputu J, Potvin D, Moyle GJ, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab 2010;95:4291-304.
44. Tebas P, Powderly WG, Claxton S, Marin D, Tantisiriwat W, Teitelbaum SL, Yarasheski KE. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000;14:F63-7. (Pubitemid 30182458)
45. Dolan SE, Huang JS, Killilea KM, Sullivan MP, Aliabadi N, Grinspoon S. Reduced bone density in HIV-infected women. AIDS 2004;18:475-83. (Pubitemid 38365875)
46. Yin M, Dobkin J, Brudney K, Becker C, Zacel J, Manandhar M, Addesso V, Shane E. Bone mass and mineral metabolism in HIV+ postmenopausal women. Osteoporos Int 2005;16:1345-52. (Pubitemid 41534646)
47. Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, Lazzarin A, Rizzardini G, Sprenger HG, Lambert J, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 2010;51:963-72.
48. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 2008;93:3499-504.
49. Gibellini D, Borderi M, De Crignis E, Cicola R, Vescini F, Caudarella R, Chiodo F, Re MC. RANKL/OPG/TRAIL plasma levels and bone mass loss evaluation in antiretroviral naive HIV-1-positive men. J Med Virol 2007;79:1446-54. (Pubitemid 47328732)
50. Dolan SE, Carpenter S, Grinspoon S. Effects of weight, body composition, and testosterone on bone mineral density in HIV-infected women. . J Acquir Immune Defic Syndr 2007;45:161-7. (Pubitemid 46869808)
51. Huang JS, Rietschel P, Hadigan CM, Rosenthal DI, Grinspoon S. Increased abdominal visceral fat is associated with reduced bone density in HIV-infected men with lipodystrophy. AIDS 2001;15:975-82. (Pubitemid 32476664)
52. Mamputu J, Soulban G, Falutz J, Huong Pham M, Marsolais C, Assaad H, Grinspoon S. Effects of tesamorelin, a growth hormone-releasing factor analogue, on bone turnover markers in HIV-infected patients with excess abdominal fat. 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, 2011.
53. Seminari E, Castagna A, Soldarini A, Galli L, Fusetti G, Dorigatti F, Hasson H, Danise A, Guffanti M, Lazzarin A, et al. Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients. HIV Med 2005;6:145-50. (Pubitemid 40740329)
54. Cozzolino M, Vidal M, Arcidiacono MV, Tebas P, Yarasheski KE, Dusso AS. HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS 2003;17:513-20. (Pubitemid 36293104)
55. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010;51:496-505.
56. Aberg JA, Kaplan JE, Libman H, Emmanuel P, Anderson JR, Stone VE, Oleske JM, Currier JS, Gallant JE. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2009;49:651-81.
57. McComsey GA, Kendall MA, Tebas P, Swindells S, Hogg E, Alston-Smith B, Suckow C, Gopalakrishnan G, Benson C, Wohl DA. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS 2007;21:2473-82. (Pubitemid 350145179)
58. Huang J, Meixner L, Fernandez S, McCutchan JA. A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. AIDS 2009;23:51-7.
59. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008;358:1304-6. (Pubitemid 351439247)
60. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-61. (Pubitemid 46780635)
61. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-99. (Pubitemid 38339363)
62. Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C, Cauley J, Leung PC, Boonen S, Santora A, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010;362:1761-71.
63. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation, 2010.